



24 August 2021

ImmuPharma PLC

("ImmuPharma" or the "Company")

Director & PDMR Share Purchases

ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that each member of the Board of Directors and PDMR, Ewa Flynn (Chief Financial Officer) have on 23 & 24 August 2021 purchased in total 670,000 ordinary shares of 10p in the Company ("Ordinary Shares").

Details of the share purchases by the Board and their current interests in shares following the transactions are set out below.

NAME & TITLE	ORDINARY SHARES PURCHASED & PURCHASE PRICE	NUMBER OF ORDINARY SHARES HELD POST TRANSACTION	% OF ISSUED SHARE CAPITAL
Tim McCarthy <i>Chairman & Chief Executive Officer</i>	250,000 @ 8.26p	288,462	0.12%
Dr Tim Franklin <i>Chief Operating Officer</i>	125,000 @ 7.99p	125,000	0.05%
Dr Sanjeev Pandya <i>Senior Non-Executive Director</i>	125,000 @ 8.00p	125,000	0.05%
Lisa Baderoon <i>Non-Executive Director & Head of Investor Relations</i>	140,000 @ 8.1957p	183,963	0.07%
Ewa Flynn <i>Chief Financial Officer & Company Secretary</i>	30,000 @ 7.892p	30,000	0.01%

Full disclosure of the transactions by persons discharging managerial responsibilities and persons closely associated with them ("PDMR's") are detailed at the end of the announcement.

End

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. on publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

For further information please contact:

ImmuPharma PLC (www.immupharma.com)

+ 44 (0) 207 152 4080

Tim McCarthy, Chairman and Chief Executive Officer

Dr Tim Franklin, Chief Operating Officer

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

SPARK Advisory Partners Limited (NOMAD)

+44 (0) 203 368 3550

Neil Baldwin

Stanford Capital Partners (Joint Broker)

+44 (0) 203 815 8880

Patrick Claridge

John Howes

Bob Pountney

SI Capital (Joint Broker)

+44 (0) 1483 413500

Nick Emerson

4Reliance (Euronext Growth Listing Sponsor)

+32 (0) 2 747 02 60

Jean-Charles Snoy

Degroof Petercam (Liquidity Provider)

+32 (0) 2 287 95 34

Erik De Clippel

Backstage Communication

Olivier Duquaine

+32 (0) 477 504 784

Gunther De Backer

+32 (0) 475 903 909

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 trial for Lupuzor™ and commercialise in the US.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Tim McCarthy	
2	Reason for the notification		
a)	Position/status	Chairman and Chief Executive Officer	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	ImmuPharma PLC	
b)	LEI	213800VZKGHXC7VUS895	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 10p each	
	Identification code	ISIN: GB0033711010	
b)	Nature of the transaction	On-market purchase	
c)	Price(s) and volume(s)	Price	Volume
		8.26p	250,000
d)	Aggregated information		
	- Aggregated volume		
	- Price		
e)	Date of the transaction	23 August 2021	
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)	

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Dr Tim Franklin	
2	Reason for the notification		
a)	Position/status	Chief Operating Officer	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	ImmuPharma PLC	
b)	LEI	213800VZKGHXC7VUS895	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 10p each	
	Identification code	ISIN: GB0033711010	
b)	Nature of the transaction	On-market purchase	
c)	Price(s) and volume(s)	Price	Volume
		7.99p	125,000
d)	Aggregated information		
	- Aggregated volume		
	- Price		
e)	Date of the transaction	24 August 2021	
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)	

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Dr Sanjeev Pandya	
2	Reason for the notification		
a)	Position/status	Senior Non-Executive Director	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	ImmuPharma PLC	
b)	LEI	213800VZKGHXC7VUS895	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 10p each	
	Identification code	ISIN: GB0033711010	
b)	Nature of the transaction	On-market purchase	
c)	Price(s) and volume(s)	Price	Volume
		8p	125,000
d)	Aggregated information		
	- Aggregated volume		
	- Price		
e)	Date of the transaction	23 August 2021	
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)	

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Lisa Baderoon	
2	Reason for the notification		
a)	Position/status	Non-Executive Director & Head of Investor Relations	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	ImmuPharma PLC	
b)	LEI	213800VZKGHXC7VUS895	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 10p each	
	Identification code	ISIN: GB0033711010	
b)	Nature of the transaction	On-market purchase	
c)	Price(s) and volume(s)	Price	Volume
		8.1957p	140,000
d)	Aggregated information		
	- Aggregated volume		
	- Price		
e)	Date of the transaction	23 August 2021	
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)	

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Ewa Flynn	
2	Reason for the notification		
a)	Position/status	Chief Financial Officer (PDMR)	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	ImmuPharma PLC	
b)	LEI	213800VZKGHXC7VUS895	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 10p each	
	Identification code	ISIN: GB0033711010	
b)	Nature of the transaction	On-market purchase	
c)	Price(s) and volume(s)	Price	Volume
		7.892p	30,000
d)	Aggregated information		
	- Aggregated volume		
	- Price		
e)	Date of the transaction	23 August 2021	
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)	